Revelation Biosciences reports Q1 net income of $6.2M; cash $17.7M; IND work ongoing

REVELATION BIOSCIENCES, INC.

2023-Q1 EPS reported $1.96

Q1 2023 net income $6.2M ($2.79 basic EPS) vs net loss $6.6M in Q1 2022; driven by $7.7M warrant liability gain.
Cash and equivalents $17.7M at March 31, 2023, up from $5.3M at Dec 31, 2022; net cash used in ops $1.6M.
Management expects existing cash to fund operations through June 2024.
IND and clinical enabling studies for REVTx-300 and REVTx-100 underway; Phase 1 start targeted Q4 2023.
Decreased clinical study expenses due to completion of prior Phase 2b and Phase 1b studies.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REVELATION BIOSCIENCES, INC. reported three months ended March 31, 2023 results: net income $6.2 million, EPS $2.79 basic earnings per share and $1.96 diluted earnings per share.

Period: three months ended March 31, 2023
Net income: $6.2 million
EPS: $2.79 basic earnings per share and $1.96 diluted earnings per share
Result: reported results

Exact text from the filing

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-023380

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.